SGRY
Surgery Partners Inc
Surgery Partners Inc historical holders
total: 1
Durable Capital Partners Surgery Partners Inc transactions over time
- Total transactions:
- 11
- New positions:
- 1
- Sold out:
- 1
- Added:
- 4
- Reduced:
- 5
- Held since:
- 2021 Q4
- Held for:
- 11 quarters
- Latest activity:
- 2024 Q3
Henry Ellenbogen has been an institutional investor in Surgery Partners Inc (SGRY) since 2021 Q4. According to 2026 Q1 report, Henry Ellenbogen doesn't hold any shares. The fund/company first acquired SGRY in 2021 Q4, initially purchasing about 1.59M shares. Since the initial investment, Durable Capital Partners has made 10 more transactions in this position.
When did Henry Ellenbogen exit their SGRY position?
Henry Ellenbogen no longer holds Surgery Partners Inc (SGRY). They sold off their entire position in 2024 Q3, closing out an investment that began in 2021 Q4.
When did Henry Ellenbogen first invest in SGRY?
Henry Ellenbogen first invested in Surgery Partners Inc (SGRY) in 2021 Q4 at the reported quarter-end price of $53.41 per share, acquiring 1,593,229 shares in their initial purchase.
What is Henry Ellenbogen's average cost basis for SGRY?
Based on historical transaction data, Henry Ellenbogen's estimated cost basis for Surgery Partners Inc (SGRY) is approximately $35.63 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $35.63
- Weighted AVG sell price:
- $25.61
SGRY transactions history by Durable Capital Partners
11 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2024 Q3
|
0.00%
|
0
|
$23.79
|
|
-100% (-2,881,227)
|
-0.56%
|
|
2024 Q2
|
0.56%
|
2,881,227
|
$23.79
|
$68,544,390
|
-39.78% (-1,903,236)
|
-0.35%
|
|
2024 Q1
|
1.11%
|
4,784,463
|
$29.83
|
$142,720,531
|
-12.65% (-692,840)
|
-0.16%
|
|
2023 Q4
|
1.38%
|
5,477,303
|
$31.99
|
$175,218,923
|
+1.94% (+104,115)
|
+0.03%
|
|
2023 Q2
|
2.12%
|
5,373,188
|
$44.99
|
$241,739,728
|
-1.40% (-76,281)
|
-0.03%
|
|
2023 Q1
|
1.76%
|
5,449,469
|
$34.47
|
$187,843,196
|
-6.91% (-404,526)
|
-0.14%
|
|
2022 Q4
|
1.70%
|
5,853,995
|
$27.86
|
$163,092,301
|
+174.29% (+3,719,766)
|
+1.08%
|
|
2022 Q3
|
0.55%
|
2,134,229
|
$23.40
|
$49,941,000
|
+25.97% (+439,949)
|
+0.11%
|
|
2022 Q2
|
0.56%
|
1,694,280
|
$28.92
|
$48,999,000
|
-11.68% (-224,170)
|
-0.06%
|
|
2022 Q1
|
0.93%
|
1,918,450
|
$55.05
|
$105,611,000
|
+20.41% (+325,221)
|
+0.16%
|
|
2021 Q4
|
0.66%
|
$53.41
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.